ICS: Advice for cell and gene therapy manufacturers amid medical breakthrough
By Albert Cooksey
The world’s first allogeneic T-cell therapy — a type of universal immunotherapy treatment that relies on donor blood — was approved in Europe earlier this month. With this scientific leap, the possibility of having a single large batch of engineered cells to potentially treat hundreds of patients is becoming a reality.
Not only is this a game changer for the medical industry, it demands innovation from the logistics industry as well. Explore the full article and gain insights from Albert Cooksey, Senior Vice President and General Manager, 3PL Services, ICS and how the organization has evolved to support this rapidly changing industry.
